- Home
- DVAX vs INVA Comparison
DVAX vs INVA Comparison
Compare DVAX & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- INVA
- Stock Information
- Founded
- DVAX 1996
- INVA 1996
- Country
- DVAX United States
- INVA United States
- Employees
- DVAX N/A
- INVA N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- INVA Biotechnology: Pharmaceutical Preparations
- Sector
- DVAX Health Care
- INVA Health Care
- Exchange
- DVAX Nasdaq
- INVA Nasdaq
- Market Cap
- DVAX 1.5B
- INVA 1.3B
- IPO Year
- DVAX 2004
- INVA 2004
- Fundamental
- Price
- DVAX $12.21
- INVA $18.90
- Analyst Decision
- DVAX Buy
- INVA Buy
- Analyst Count
- DVAX 2
- INVA 1
- Target Price
- DVAX $22.00
- INVA N/A
- AVG Volume (30 Days)
- DVAX 3.3M
- INVA 575.7K
- Earning Date
- DVAX 11-07-2024
- INVA 11-06-2024
- Dividend Yield
- DVAX N/A
- INVA N/A
- EPS Growth
- DVAX N/A
- INVA 46.55
- EPS
- DVAX 0.15
- INVA 0.99
- Revenue
- DVAX $260,810,000.00
- INVA $352,745,000.00
- Revenue This Year
- DVAX $23.13
- INVA $14.10
- Revenue Next Year
- DVAX $19.60
- INVA N/A
- P/E Ratio
- DVAX $80.80
- INVA $19.08
- Revenue Growth
- DVAX N/A
- INVA 21.46
- 52 Week Low
- DVAX $9.74
- INVA $13.41
- 52 Week High
- DVAX $15.01
- INVA $21.28
- Technical
- Relative Strength Index (RSI)
- DVAX 52.22
- INVA 35.97
- Support Level
- DVAX $11.61
- INVA $18.40
- Resistance Level
- DVAX $13.74
- INVA $21.28
- Average True Range (ATR)
- DVAX 0.52
- INVA 0.61
- MACD
- DVAX 0.09
- INVA -0.08
- Stochastic Oscillator
- DVAX 32.80
- INVA 17.36
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties and innovative healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.